Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension

Jeffrey (Jeff) Gold, Suzanne Cullinane, Jonathan Chen, Mehmet C. Oz, Juan A. Oliver, Donald W. Landry

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Objective: To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors. Design: Retrospective analysis of existing data. Setting: The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. Patients: Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of ≥90 mm Hg. Interventions: Vasopressin was administered to the three patients. Measurements and Main Results: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90 ± 4.7 to 130 ± 2.3 mm Hg while reducing the administration of catecholamine pressors. Conclusions: Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.

Original languageEnglish (US)
Pages (from-to)249-252
Number of pages4
JournalCritical Care Medicine
Volume28
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Controlled Hypotension
Milrinone
Vasopressins
Norepinephrine
Type 3 Cyclic Nucleotide Phosphodiesterases
Catecholamines
Hypotension
Arterial Pressure
Blood Pressure
Cardiotonic Agents
Phosphodiesterase Inhibitors
Therapeutics
Critical Care
Vascular Smooth Muscle
Intensive Care Units

Keywords

  • Hypotension
  • Milrinone
  • Norepinephrine
  • Phosphodiesterase inhibitor
  • Vasopressin
  • Vasopressor

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Gold, J. J., Cullinane, S., Chen, J., Oz, M. C., Oliver, J. A., & Landry, D. W. (2000). Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Critical Care Medicine, 28(1), 249-252.

Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. / Gold, Jeffrey (Jeff); Cullinane, Suzanne; Chen, Jonathan; Oz, Mehmet C.; Oliver, Juan A.; Landry, Donald W.

In: Critical Care Medicine, Vol. 28, No. 1, 2000, p. 249-252.

Research output: Contribution to journalArticle

Gold, JJ, Cullinane, S, Chen, J, Oz, MC, Oliver, JA & Landry, DW 2000, 'Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension', Critical Care Medicine, vol. 28, no. 1, pp. 249-252.
Gold, Jeffrey (Jeff) ; Cullinane, Suzanne ; Chen, Jonathan ; Oz, Mehmet C. ; Oliver, Juan A. ; Landry, Donald W. / Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. In: Critical Care Medicine. 2000 ; Vol. 28, No. 1. pp. 249-252.
@article{92c808fa5f71405bbadc41be811ca16a,
title = "Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension",
abstract = "Objective: To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors. Design: Retrospective analysis of existing data. Setting: The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. Patients: Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of ≥90 mm Hg. Interventions: Vasopressin was administered to the three patients. Measurements and Main Results: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90 ± 4.7 to 130 ± 2.3 mm Hg while reducing the administration of catecholamine pressors. Conclusions: Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.",
keywords = "Hypotension, Milrinone, Norepinephrine, Phosphodiesterase inhibitor, Vasopressin, Vasopressor",
author = "Gold, {Jeffrey (Jeff)} and Suzanne Cullinane and Jonathan Chen and Oz, {Mehmet C.} and Oliver, {Juan A.} and Landry, {Donald W.}",
year = "2000",
language = "English (US)",
volume = "28",
pages = "249--252",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension

AU - Gold, Jeffrey (Jeff)

AU - Cullinane, Suzanne

AU - Chen, Jonathan

AU - Oz, Mehmet C.

AU - Oliver, Juan A.

AU - Landry, Donald W.

PY - 2000

Y1 - 2000

N2 - Objective: To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors. Design: Retrospective analysis of existing data. Setting: The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. Patients: Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of ≥90 mm Hg. Interventions: Vasopressin was administered to the three patients. Measurements and Main Results: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90 ± 4.7 to 130 ± 2.3 mm Hg while reducing the administration of catecholamine pressors. Conclusions: Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.

AB - Objective: To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III inhibition. Phosphodiesterase III inhibitors are cardiotonic agents that increase myocardial contractility and decrease vascular smooth muscle tone. The vasodilatory effect can be profound, and the resulting hypotension frequently requires the administration of catecholamine pressors. Design: Retrospective analysis of existing data. Setting: The medical or surgical intensive care unit of Columbia-Presbyterian Medical Center. Patients: Three consecutive patients receiving milrinone and requiring catecholamine pressors to maintain systolic arterial pressure of ≥90 mm Hg. Interventions: Vasopressin was administered to the three patients. Measurements and Main Results: Vasopressin (0.03-0.07 units/min) increased systolic arterial pressure from 90 ± 4.7 to 130 ± 2.3 mm Hg while reducing the administration of catecholamine pressors. Conclusions: Vasopressin at very low doses appears to be an effective vasopressor for milrinone-induced hypotension.

KW - Hypotension

KW - Milrinone

KW - Norepinephrine

KW - Phosphodiesterase inhibitor

KW - Vasopressin

KW - Vasopressor

UR - http://www.scopus.com/inward/record.url?scp=0033968013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033968013&partnerID=8YFLogxK

M3 - Article

C2 - 10667533

AN - SCOPUS:0033968013

VL - 28

SP - 249

EP - 252

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1

ER -